Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mayer Fishman

Showing results (51-60 of 69) with videos related to

Pageof 7
Sort By:
JAMA Oncology|September 5, 2018
Downstaging and Survival Outcomes Associated With Neoadjuvant Chemotherapy Regimens Among Patients Treated With Cystectomy for Muscle-Invasive Bladder CancerCharles C Peyton, Dominic Tang, Richard R Reich, et al.
Cancer|June 14, 2012
AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 studyBrian Rini, Cezary Szczylik, Nizar M Tannir, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 26, 2016
Tyrosine Kinase Signaling in Clear Cell and Papillary Renal Cell Carcinoma Revealed by Mass Spectrometry-Based Phosphotyrosine ProteomicsScott M Haake, Jiannong Li, Yun Bai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2010
Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancerSrinivas Nagaraj, Je-In Youn, Hannah Weber, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2006
Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic studyGeorge R Simon, Christopher R Garrett, Stephen C Olson, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 25, 2007
Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinomaMayer Fishman, Terri B Hunter, Hatem Soliman, et al.
Immunotherapy|April 20, 2012
Serial assessment of lymphocytes and apoptosis in the prostate during coordinated intraprostatic dendritic cell injection and radiotherapySteven Eric Finkelstein, Francisco Rodriguez, Mary Dunn, et al.
Nature Medicine|July 13, 2010
Lipid accumulation and dendritic cell dysfunction in cancerDonna L Herber, Wei Cao, Yulia Nefedova, et al.
Cancer|April 6, 2019
A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinomaMartin H Voss, Rupal S Bhatt, Nicholas J Vogelzang, et al.
Nature Communications|May 25, 2026
Pembrolizumab plus high-dose IL-2 in advanced clear cell renal cell carcinoma: six-year survival outcomes and molecular signatures from a phase 2 trialJeffrey S Johnson, Justin W Miller, Firas Hatoum, et al.
Pageof 7

Showing results (51-60 of 69) with videos related to

Sort By:
Pageof 7
JAMA Oncology|September 5, 2018
Downstaging and Survival Outcomes Associated With Neoadjuvant Chemotherapy Regimens Among Patients Treated With Cystectomy for Muscle-Invasive Bladder CancerCharles C Peyton, Dominic Tang, Richard R Reich, et al.
Cancer|June 14, 2012
AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 studyBrian Rini, Cezary Szczylik, Nizar M Tannir, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 26, 2016
Tyrosine Kinase Signaling in Clear Cell and Papillary Renal Cell Carcinoma Revealed by Mass Spectrometry-Based Phosphotyrosine ProteomicsScott M Haake, Jiannong Li, Yun Bai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2010
Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancerSrinivas Nagaraj, Je-In Youn, Hannah Weber, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2006
Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic studyGeorge R Simon, Christopher R Garrett, Stephen C Olson, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 25, 2007
Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinomaMayer Fishman, Terri B Hunter, Hatem Soliman, et al.
Immunotherapy|April 20, 2012
Serial assessment of lymphocytes and apoptosis in the prostate during coordinated intraprostatic dendritic cell injection and radiotherapySteven Eric Finkelstein, Francisco Rodriguez, Mary Dunn, et al.
Nature Medicine|July 13, 2010
Lipid accumulation and dendritic cell dysfunction in cancerDonna L Herber, Wei Cao, Yulia Nefedova, et al.
Cancer|April 6, 2019
A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinomaMartin H Voss, Rupal S Bhatt, Nicholas J Vogelzang, et al.
Nature Communications|May 25, 2026
Pembrolizumab plus high-dose IL-2 in advanced clear cell renal cell carcinoma: six-year survival outcomes and molecular signatures from a phase 2 trialJeffrey S Johnson, Justin W Miller, Firas Hatoum, et al.
Pageof 7